WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
1. (WO2008060375) UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/060375    International Application No.:    PCT/US2007/021461
Publication Date: 22.05.2008 International Filing Date: 05.10.2007
IPC:
A61K 31/00 (2006.01), A61K 31/4525 (2006.01), A61K 31/453 (2006.01), A61K 31/454 (2006.01), A61K 31/498 (2006.01), A61K 31/536 (2006.01), A61K 31/5365 (2006.01), A61K 31/5415 (2006.01), A61P 25/28 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNINA [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607 (US) (For All Designated States Except US).
LAUTERBORN, Julie [US/US]; (US) (For US Only).
LYNCH, Gary [US/US]; (US) (For US Only).
GALL, Christine [US/US]; (US) (For US Only).
REX, Christopher [US/US]; (US) (For US Only)
Inventors: LAUTERBORN, Julie; (US).
LYNCH, Gary; (US).
GALL, Christine; (US).
REX, Christopher; (US)
Agent: HUNTER, Tom; Beyer Weaver LLP, P.O. Box 70250, Oakland, CA 94612-0250 (US)
Priority Data:
60/849,925 06.10.2006 US
60/977,011 02.10.2007 US
Title (EN) UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION
(FR) RÉGULATION POSITIVE DE NIVEAUX DE BDNF POUR ATTÉNUER UN RETARD MENTAL
Abstract: front page image
(EN)This invention provides methods of preserving, improving, or restoring cognitive function in mammal having one or more mutations in the FMRl gene (e.g. at risk for or having fragile x syndrome), where the methods involve the brain derived neurotrophic factor (BDNF) level or activity in the brain of said mammal. In certain embodiments the methods involve administering one or more AMPA potentiators (e.g., ampakines) to the mammal in an amount sufficient to increase BDNF levels in the brain of the mammal.
(FR)L'invention fournit des procédés pour préserver, améliorer ou restaurer une fonction cognitive chez un mammifère ayant un ou plusieurs mutations dans le gène FMR1 (par exemple susceptible de développer ou ayant un syndrome x fragile), lesquels procédés impliquent le niveau de facteur neurotrophique dérivé du cerveau (BDNF) ou l'activité dans le cerveau du mammifère. Dans certains modes de réalisation, les procédés impliquent l'administration d'un ou plusieurs potentialisateurs des AMPA (par exemple des ampakines) au mammifère, en une quantité suffisante pour augmenter les niveaux de BDNF dans le cerveau du mammifère.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)